EDIT vs. CCCC, TSHA, ADPT, VYGR, ITOS, LXEO, FATE, ALLO, ALVO, and ALEC
Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include C4 Therapeutics (CCCC), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), Allogene Therapeutics (ALLO), Alvotech (ALVO), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine (NASDAQ:EDIT) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.
Editas Medicine has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500.
Editas Medicine currently has a consensus target price of $15.00, suggesting a potential upside of 197.91%. C4 Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 58.91%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Editas Medicine is more favorable than C4 Therapeutics.
In the previous week, Editas Medicine had 10 more articles in the media than C4 Therapeutics. MarketBeat recorded 13 mentions for Editas Medicine and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.00 beat Editas Medicine's score of -0.13 indicating that C4 Therapeutics is being referred to more favorably in the news media.
C4 Therapeutics has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Editas Medicine received 277 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 54.04% of users gave Editas Medicine an outperform vote while only 37.50% of users gave C4 Therapeutics an outperform vote.
Editas Medicine has a net margin of -196.12% compared to C4 Therapeutics' net margin of -638.34%. Editas Medicine's return on equity of -42.95% beat C4 Therapeutics' return on equity.
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 8.0% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Editas Medicine beats C4 Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Editas Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Editas Medicine Competitors List
Related Companies and Tools
